Wipfli: Healthcare organizations may be overlooking revenue they've already earned

Wipfli argues healthcare providers can improve cash flow without adding staff or technology by preventing revenue leakage, strengthening denial ownership and prioritizing high-value aging receivables. Its examples include nearly $4.9 million in denied dollars at a Critical Access Hospital, including more than $1.25 million tied to one preventable denial category; preventing half could recover about $625,000 and avoid roughly 1,700 reworked claims. A three-provider practice also identified about $50,000 of underpayments and recovered approximately $35,000 after correcting fee-schedule issues.

Analysis

This is not a sector-level earnings catalyst; it is a reminder that provider liquidity is increasingly determined by administrative execution rather than utilization alone. Hospitals with elevated commercial-payer mix and decentralized front-end operations have the most upside from cleaner claims and underpayment recovery, but the benefit is likely to accrue unevenly and be partially reinvested into labor, IT, or payer-contracting resources rather than flow directly to EBITDA.

The investable read-through favors revenue-cycle technology and outsourced-services vendors over providers. RCM platforms such as Waystar (WAY), R1 RCM (RCM), and Oracle Health/Cerner (ORCL) can benefit if CFOs shift budgets from broad expansion initiatives toward measurable cash-conversion projects; however, providers may prefer workflow redesign before new software, limiting near-term software demand. UnitedHealth/Optum (UNH) is a nuanced beneficiary through provider-services exposure, while aggressive payer edit practices can also create the very denial complexity that sustains RCM spending.

Over 1-3 months, watch provider commentary on cash collections, AR days, initial-denial rates, and outsourced billing demand during earnings calls. Over 6-18 months, persistent labor scarcity makes automation of eligibility, prior authorization, coding, and claims follow-up structurally attractive, but AI-enabled functionality could compress standalone RCM vendor pricing if it becomes embedded in EHR systems. The contrarian view is that better provider controls reduce rework volumes and eventually shrink transaction-based outsourcing revenue; vendors with SaaS, analytics, and workflow-automation pricing are better positioned than labor-heavy service models.

No immediate broad healthcare trade is warranted from a consultancy marketing release. A stronger signal would be sequential evidence of provider cash conversion improving without corresponding volume growth, or a rise in RCM bookings/backlog that validates a budget-cycle inflection.

Key Decisions for Investors

• Maintain a watchlist long bias toward WAY versus labor-intensive RCM peers over the next 6-12 months; initiate only if quarterly bookings and net revenue retention indicate providers are funding automation rather than merely consulting projects. Thesis fails if sales cycles lengthen or management guides to weaker provider IT budgets.
• Monitor RCM for a tactical catalyst around provider earnings over the next 1-3 months: consider long exposure only if hospital systems cite rising denial-management outsourcing or AR-cleanup programs and RCM's volume/revenue outlook is revised upward. Avoid treating the release itself as an entry signal.
• Pair-trade research: long WAY / short ORCL is attractive only if evidence emerges that independent RCM automation is winning incremental workflows from EHR-native tools; use a 6-12 month horizon. Falsify if Oracle reports accelerating healthcare applications bookings or major EHR integrations displace third-party workflow vendors.
• For provider holdings, screen HCA, THC, CYH, and UHS for AR days, bad-debt trends, and cash-flow conversion versus EBITDA. Favor operators demonstrating lower administrative leakage without rising SG&A; avoid assuming a one-time AR recovery represents recurring earnings quality.